Evaluating Cell Therapy CDMOs: What Matters Most?

In this Outsourced Pharma Cell Therapy Capabilities Update, Kincell Bio discusses how cell therapy manufacturers support programs across the development lifecycle, and how different approaches can help reduce risk as therapies advance toward the clinic and commercialization.

Whether you’re evaluating manufacturing partners, planning a technology transfer, or preparing for future scale-up, this session offers valuable insights into the considerations that shape successful cell therapy programs.

Featured Speakers from Kincell Bio:

Stewart McNaull, PhD, Chief Commercial Officer

Matt Haines, Chief Operations Officer

Access the full Outsourced Pharma Cell Therapy Capabilities Update presentation to learn how Kincell Bio helps innovators move from development to commercialization with confidence.